Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Peter Schmid"'
Autor:
Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney
Publikováno v:
Journal of Clinical Oncology. 40:LBA1001-LBA1001
LBA1001 Background: HR+/HER2– disease is the most common subtype of metastatic breast cancer (MBC). Treatment includes sequential endocrine therapy combined with targeted agents followed by single-agent chemotherapy, with increasingly shorter durat
Autor:
Luciana Molinero, Leisha A. Emens, Leonard D. Goldstein, Alexander R. Abbas, Hartmut Koeppen, Hope S. Rugo, Sylvia Adams, Stephen Y. Chui, Peter Schmid, Sherene Loi
Publikováno v:
Journal of Clinical Oncology. 40:1078-1078
1078 Background: In the IMpassion130 study (NCT02425891) first-line atezolizumab plus nab-paclitaxel (A+nP) provided clinical benefit compared with placebo plus nP (P+nP) in patients with mTNBC whose tumors were PD-L1+ (Schmid NEJM 2018). However, in
Autor:
Hope S. Rugo, Joohyuk Sohn, Yolanda Jerez Gilarranz, Lucia Gonzalez-Cortijo, Amir Sonnenblick, Dhanusha Sabanathan, Ernesto Pablo Korbenfeld, Daniel Egle, Brigitte Poirier, Flora Zagouri, Alexios Matikas, Sercan Aksoy, Umut Demirci, Pier Ramos-Elias, Seock-Ah Im, Fatima Cardoso, Liyi Jia, Carlos Baccan, Konstantinos Tryfonidis, Peter Schmid
Publikováno v:
Journal of Clinical Oncology. 40:TPS1118-TPS1118
TPS1118 Background: HR+/HER2− advanced breast cancer that progresses on endocrine therapy is treated with chemotherapy (chemo). The phase 1b KEYNOTE-028 trial showed durable activity with pembrolizumab (pembro) monotherapy in previously treated HR+
Autor:
Philippe L. Bedard, Melissa Kate Accordino, Andres Cervantes, Valentina Gambardella, Erika P. Hamilton, Antoine Italiano, Dejan Juric, Kevin Kalinsky, Ian E. Krop, Mafalda Oliveira, Cristina Saura, Peter Schmid, Nicholas C. Turner, Andreea Varga, Noopur Shankar, Jennifer Schutzman, Stephanie Royer-Joo, Miguel Valero Martin, Komal L. Jhaveri
Publikováno v:
Journal of Clinical Oncology. 40:1052-1052
1052 Background: Dysregulating mutations in PIK3CA, encoding the PI3K p110α subunit, occur in ̃40% of HR+/HER2– BCs. Inavolisib is a PI3Kα-specific inhibitor that also promotes degradation of mutant p110α. It has demonstrated encouraging prelim
Autor:
Sarah Rogerson, Howard Turner, Angela Bilkhu, Estefania Monturus, Adam Knott, Eleonora Restuccia, Nigel Quashie, Duncan Wheatley, Leslie Gilham, Sara A. Hurvitz, Peter Schmid, Thomas Bachelot, Giampaolo Bianchini, Nadia Harbeck, Sherene Loi, Yeon Hee Park, Aleix Prat, Tracy Simkins
Publikováno v:
Journal of Clinical Oncology. 40:e12504-e12504
e12504 Background: Representative pt populations in clinical trials are essential to address healthcare disparities between different racial/ethnic groups, including treatment access and pt outcomes. Many clinical trials mainly include White pts, whi
Autor:
Michelino De Laurentiis, Luis Costa, Joseph Gligorov, Ann Knop, Elzbieta Senkus-Konefka, José A. García-Sáenz, Peter Schmid, Aurelia Heniquez, Paolo Serra, Albert Reising, Sherko Kuemmel
Publikováno v:
Journal of Clinical Oncology. 40:TPS1109-TPS1109
TPS1109 Background: Endocrine therapy (ET) + CDK4/6i is standard of care for HR+, HER2− ABC; however, CDK4/6i resistance, in which the phosphatidylinositol-3-kinase (PI3K) pathway has a key role, remains challenging. Progression-free survival (PFS)
Autor:
Fabrice Andre, Erika P. Hamilton, Sherene Loi, Seock-Ah Im, Joohyuk Sohn, Ling-Ming Tseng, Carey K. Anders, Peter Schmid, Sarice Boston, Annie Darilay, Pia Maarit Herbolsheimer, Adam Konpa, Gargi Patel, Tinghui Yu, Magdalena Wrona, Komal L. Jhaveri
Publikováno v:
Journal of Clinical Oncology. 40:3025-3025
3025 Background: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody and a topoisomerase I inhibitor payload, is approved for pts with unresectable or metastatic HER2+ BC with ≥2 prior an
Autor:
Luciana Molinero, Xiangnan Guan, Regula Deurloo, Yosi Gozlan, Hila Sharim, Leisha A. Emens, David A. Cameron, Peter Schmid, David Miles, Sylvia Adams, Stephen Y. Chui, Sanjeev Mariathasan, Joyce O'Shaughnessy, Fabrice Andre, Sherene Loi
Publikováno v:
Journal of Clinical Oncology. 40:1083-1083
1083 Background: The immune checkpoint inhibitor (ICI) atezo showed disparate outcomes as first-line therapy for metastatic TNBC when combined with nab-paclitaxel (nPac) in IMpassion130 [Schmid 2018] vs solvent-based paclitaxel (Pac) in IMpassion131
Autor:
Maria Cortes, Alfonso Cortés Salgado, Serafin Morales Murillo, Isabel Blancas, Patricia Cortez, Isabel Calvo Plaza, Nieves Diaz Fernandez, Alejandro Martinez-Bueno, Manuel Ruiz-Borrego, Salvador Blanch, Elisenda Llabres, Frederik Marmé, Peter Schmid, Valentina Guarneri, Joseph Gligorov, José Manuel Pérez-García, Miguel Sampayo-Cordero, Andrea Malfettone, Antonio Llombart Cussac, Javier Cortes
Publikováno v:
Journal of Clinical Oncology. 40:1084-1084
1084 Background: A substantial benefit from adding an immune checkpoint inhibitor to chemotherapy (CT) was reported in mTNBC patients (pts) with PD-L1+ tumors. However, many pts still have a poor outcome. ATRACTIB is exploring the synergism between A
Autor:
Lajos Pusztai, Carsten Denkert, Joyce O'Shaughnessy, Javier Cortes, Rebecca Alexandra Dent, Heather L. McArthur, Sherko Kuemmel, Jonas C. S. Bergh, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Yalin Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid
Publikováno v:
Journal of Clinical Oncology. 40:503-503
503 Background: KEYNOTE-522 (NCT03036488) tested the benefit from adding pembrolizumab (pembro) to chemotherapy (chemo) in patients (pts) with early TNBC. The primary results showed statistically significant and clinically meaningful improvements in